Cantor Fitzgerald Raises PT and Estimates on NewLink Genetics (NLNK); Great Data at ASCO

June 6, 2012 7:18 AM EDT
Get Alerts NLNK Hot Sheet
Price: $0.89 --0%

Rating Summary:
    1 Buy, 4 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Cantor Fitzgerald maintains a 'Buy' on NewLink Genetics (NASDAQ: NLNK) price target of $18.00 (from $15.00).

Analyst, Mara Goldstein, said, "We are raising our 12-month price target to $18 based on our view that the Phase II data generated by HyperAcute Pancreas provides some de-risking to the Phase III trial, prompting us to reduce our five-year discount rate to 45% from 50%."

"We like NewLink for its pipeline of products addressing large and lucrative unmet medical needs and have greater enthusiasm post-ASCO given data presented...We have also updated our estimates to reflect 1Q:12 actual results. Based on a higher share count our new EPS forecast for 2012 is ($1.77) from ($2.98) and our 2013 forecast is now (2.07)."

For an analyst ratings summary and ratings history on NewLink Genetics click here. For more ratings news on NewLink Genetics click here.

Shares of NewLink Genetics closed at $12.41 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change

Related Entities

Cantor Fitzgerald